SG&A at other companies
Other financials
Where this comes from
Reported directly by Collegium Pharmaceutical, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Collegium Pharmaceutical, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Collegium Pharmaceutical, Inc.'s SG&A?
- Collegium Pharmaceutical, Inc. (COLL) reported SG&A of $86.35M in Q1 2026.
- How has Collegium Pharmaceutical, Inc.'s SG&A changed year-over-year?
- Collegium Pharmaceutical, Inc.'s SG&A increased by 13.0% year-over-year, from $76.42M to $86.35M.
- What is the long-term trend for Collegium Pharmaceutical, Inc.'s SG&A?
- Over 4 years (2021 to 2025), Collegium Pharmaceutical, Inc.'s SG&A has grown at a 24.4% compound annual growth rate (CAGR), from $118.96M to $284.8M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.